Etrasimod (Velsipity®). HTA ID: 24012

Assessment Status Rapid Review Complete
HTA ID 24012
Drug Etrasimod
Brand (Velsipity®
Indication Etrasimod (Velsipity®) is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
Assessment Process
Rapid review commissioned 11/05/2024
Rapid review completed 07/05/2024
Rapid review outcome A full HTA is not recommended. The NCPE recommends that etrasimod not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.